Polymerase chain reaction (PCR) measure of residual molecular disease is routinely used to monitor quantitatively unique AML-defining translocations and mutations in APL, CBF AML, NPM1-mutated AML, and now expanding to other molecular subsets (IDH1/2 and FLT3 mutations). This evidence concerns the gene CEBPZ and acute myeloid leukemia.